



THE BOARD OF DIRECTORS OF IMMUNOVIA WITHDRAWS PROPOSAL FOR REVERSE SHARE SPLIT AND CANCELS EXTRAORDINARY GENERAL MEETING

Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary General Meeting to be held on 22 January 2026 is thus cancelled.

Since the Board of Directors' proposal for a reverse share split and notice of an Extraordinary General Meeting were announced on 17 December 2025, Immunovia's Board of Directors has discussed the proposal with additional several major shareholders. Based on their feedback and the notifications to participate in the general meeting, Immunovia's Board of Directors believes the proposal will not achieve the required two-thirds majority at the general meeting. The Board of Directors of Immunovia has thus decided to withdraw the proposal for a reverse share split, which was subject to approval by the Extraordinary General Meeting on 22 January 2026, as well as cancel the Extraordinary General Meeting in its entirety.

For further information, please contact

Jeff Borcherding, CEO

jeff.borcherding@immunovia.com

The information was submitted for publication, through the agency of the contact person set out above, on 20 January 2026 at 07:30 CET.

Immunovia in brief

Immunovia is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.